Ignite Creation Date:
2025-12-24 @ 9:38 PM
Ignite Modification Date:
2025-12-25 @ 7:21 PM
Study NCT ID:
NCT00900432
Status:
COMPLETED
Last Update Posted:
2015-12-03
First Post:
2009-05-09
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Immune Response in Peripheral Blood of Patients With Colon Cancer
Sponsor:
University of Arizona
Organization:
Study Overview
Official Title:
Immune Studies of Peripheral Blood From Patients With Malignant Disease Gastrointestinal Tract
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in the immune system that may help kill cancer cells.
PURPOSE: This laboratory study is looking at anticancer immune responses in the peripheral blood of patients with colon cancer.
PURPOSE: This laboratory study is looking at anticancer immune responses in the peripheral blood of patients with colon cancer.
Detailed Description:
OBJECTIVES:
* Quantify T cells specific for tumor peptides (carcinoembryonic antigen and MUC1) from the peripheral blood of patients with colon cancer.
OUTLINE: This is an open-label study.
Patients undergo blood collection at time of follow-up, surgery, thoracentesis, paracentesis, or leukapheresis (≤ 5 times per year). Blood is analyzed for tumor peptides (carcinoembryonic antigen and MUC1), circulating cytokines, and lymphocyte response by ELISA, ELISPOT, or intracellular flow.
PROJECTED ACCRUAL: A total of 140 patients will be accrued for this study.
* Quantify T cells specific for tumor peptides (carcinoembryonic antigen and MUC1) from the peripheral blood of patients with colon cancer.
OUTLINE: This is an open-label study.
Patients undergo blood collection at time of follow-up, surgery, thoracentesis, paracentesis, or leukapheresis (≤ 5 times per year). Blood is analyzed for tumor peptides (carcinoembryonic antigen and MUC1), circulating cytokines, and lymphocyte response by ELISA, ELISPOT, or intracellular flow.
PROJECTED ACCRUAL: A total of 140 patients will be accrued for this study.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| P50CA095060 | NIH | None | https://reporter.nih.gov/quic… | View |
| P30CA023074 | NIH | None | https://reporter.nih.gov/quic… | View |
| UARIZ-04-81 | OTHER | CDR0000491215 | View |